Clinical Trial

Imaging of Solid Tumors Using 18F-TRX

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This phase I trial tests the safety and effectiveness of 18F-TRX in detecting tumors (cancer) patients with solid tumors. 18F-TRX is an imaging tracer that is used to visualize tumors using a PET scan. It specifically targets and detects labile (unstable) iron levels within tissues, including tumors. Diagnostic procedures, such as 18F-TRX PET/CT or PET/MRI, may help detect tumors in patients with solid tumors
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-09-30 -> 2027-09-30 2026-07-24
minor Completion pushed: 2026-09-30 -> 2027-09-30 2026-07-24
Trial Details
NCT Number NCT06942104
Lead Sponsor Rahul Aggarwal
Collaborators: United States Department of Defense
Conditions Solid Tumor, Solid Carcinoma, Castration-Resistant Prostate Carcinoma, Locally Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8 +2 more
Enrollment 56 participants
Start Date 2025-07-03
Primary Completion 2027-09-30 (estimated)
Study Completion 2027-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-23